Advertisement
News
Subscribe to MDT Magazine News

Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V®

April 3, 2011 7:34 am | by Bio-Medicine.Org | Comments

NEW ORLEANS, April 3, 2011 /- A pooled analysis of the SPIRIT II, III, IV and COMPARE trials presented today further reinforces the positive clinical performance of Abbott's (NYSE: ABT ) market-leading XIENCE V ® Everolimus Eluting Coronary Stent System. As part of the analysis of...

TOPICS:

Boston Scientific IONâ„¢ Platinum Chromium Stent System Demonstrates Strong Performance in Analysis of PERSEUS and TAXUS ATLAS Clinical Trial Data

April 3, 2011 7:33 am | by Bio-Medicine.Org | Comments

NATICK, Mass. and NEW ORLEANS, April 3, 2011 /- Boston Scientific Corporation (NYSE: BSX ) today announced results from a pooled patient-level analysis of its PERSEUS and TAXUS ATLAS clinical trial data, demonstrating differences in safety and efficacy outcomes favoring the...

TOPICS:

Young black athletes with sickle cell trait might be susceptible to sudden death

April 3, 2011 12:37 am | by EurekAlert | Comments

(Minneapolis Heart Institute Foundation) The sickle cell trait could be a cause -- albeit rare -- of sudden death in young African-American competitive athletes, most commonly during football training, according to a scientific poster that will be presented at the American College...

TOPICS:
Advertisement

Scientists Identify KRAS Rearrangements in Metastatic Prostate Cancer

April 2, 2011 9:31 pm | by AACR | Comments

Tweet • Genetic information may allow doctors to determine cancer prognosis. • KRAS is a known “oncogene” that leads to cancer. ORLANDO, Fla. - Scientists have uncovered a genetic characteristic of metastatic prostate cancer that defines a rare sub-type of this disease. These findings are...

TOPICS:

Digoxin May be a Possible Treatment for Prostate Cancer

April 2, 2011 9:31 pm | by AACR | Comments

Tweet • Digoxin has a long history as a treatment for heart failure. • New testing paradigm combined epidemiological and laboratory testing. • Repositioning existing therapies could speed drug approval time. ORLANDO, Fla. - Scientists have identified digoxin as a possible therapy for...

TOPICS:

New target identified for squamous cell lung cancer

April 2, 2011 8:34 pm | by EurekAlert | Comments

(American Association for Cancer Research) Scientists at the Dana Farber Cancer Institute have identified a mutation in the DDR2 gene that may indicate which patients with squamous cell lung cancer will respond to dasatinib.

TOPICS:

Chronic Stress of Cancer Causes Accelerated Telomere Shortening

April 2, 2011 12:35 pm | by AACR | Comments

Tweet • Telomere shortening is associated with deterioration of chromosomes. • Reducing chronic stress modulates telomere shortening. • Research presented during an AACR press conference. ORLANDO, Fla. - Results of a study presented at the AACR 102nd Annual Meeting 2011, held here April...

TOPICS:

Genetic Variation Linked to Longer Telomeres and Lower Risk of Bladder Cancer

April 2, 2011 12:34 pm | by AACR | Comments

Tweet • Telomere length tends to shorten with age and stress. • Interventions to lengthen telomeres key to cancer interception. • Research simultaneously published in Cancer Prevention Research. ORLANDO, Fla. - Using new genetic information, scientists have linked a commonly found human...

TOPICS:
Advertisement

Optimer Pharmaceuticals Announces Presentation at SHEA of Data Highlighting the Burden of Clostridium difficile Infection (CDI) in Hospital Patients

April 2, 2011 11:35 am | by Bio-Medicine.Org | Comments

SAN DIEGO, April 2, 2011 /- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR ) announced today the presentation of information from insurance claims and survey databases highlighting the unmet need for targeted therapies to treat subpopulations at high risk of recurrence of Clostridium...

TOPICS:

DNA of 50 Breast Cancer Patients Decoded

April 2, 2011 6:33 am | by AACR | Comments

Tweet • Reveals complexity and hints toward personalized medicine. • Patient tumors had more than 1,700 mutations. • Abstract to be presented during an AACR press conference. ORLANDO, Fla. - In one of the largest cancer genomics investigations reported to date, scientists have sequenced...

TOPICS:

Target for Lung Cancer Chemoprevention Identified

April 2, 2011 6:33 am | by AACR | Comments

Tweet • Endobronchial dysplasia can be modified pharmacologically. • Effect on endobronchial dysplasia was seen in former smokers. • Full study details to be presented at AACR press conference. ORLANDO, Fla. - Scientists have identified a biomarker for measuring the success of lung cancer...

TOPICS:

Combining MEK and PI3K Inhibitors Appears Encouraging in a Safety Study with Early Signs of Anti-tumor Activity

April 2, 2011 6:33 am | by AACR | Comments

Tweet • Combination therapy targets MEK and PI3K pathways. • Phase I trials of single agent MEK and PI3K pathway inhibitors alone have shown signs of anti-tumor activity. • Abstract to be presented at AACR press conference. ORLANDO, Fla. - The combination of two compounds that inhibit two...

TOPICS:

BATTLE Researchers Identify New Biomarkers for EGFR Inhibition

April 2, 2011 6:33 am | by AACR | Comments

Tweet • Protocol was one of the first to treat patients based on molecular profiling. • Two gene signatures were predictive of efficacy for erlotinib. • Updated results to be presented during AACR press conference. ORLANDO, Fla. - Scientists are continuing their work on the...

TOPICS:

New Inhibitor Prevented Lesions, Reduced Tumor Size in Basal Cell Cancer

April 2, 2011 6:32 am | by AACR | Comments

Tweet • Tumors decreased by 24 cm in patients who received GDC-0449. • No patients receiving GDC-0449 required surgery to remove tumors. • Data safety monitoring board stopped placebo arm at interim analysis. ORLANDO, Fla. - A new hedgehog pathway inhibitor demonstrated efficacy in...

TOPICS:

Data suggest liver experts should take care when prescribing novel antiviral HCV drugs

April 2, 2011 12:37 am | by EurekAlert | Comments

(European Association for the Study of the Liver) Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus must be prescribed and monitored by experts and specialists to ensure resistance is minimized.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading